The influence of biologic factors on the surgical decision in advanced neuroblastoma

Annals of Surgical Oncology

Volumn 13, Issue 2, 2006, Pages 238-244

  Hsu, Wen Ming ^a   Jen, Yung Ming ^a   Lee, Hsinyu ^b   Kuo, Min Liang ^c   Tsao, Po Nien ^a   Chen, Chiung Nien ^a   Lai, Dar Ming ^a   Lin, Ming Tsan ^a   Lai, Hong Shiee ^a   Chen, Wei Jao ^a   Hsieh, Fon Jou ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

MYCN; Neuroblastoma; Surgery; Trk A

Indexed keywords

BIOLOGICAL FACTOR; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; PROTEIN TYROSINE KINASE A;

ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; MALE; MYELOID LEUKEMIA; NEUROBLASTOMA; PROGNOSIS; TREATMENT INDICATION; VIRUS ONCOGENE;

CHILD; CHILD, PRESCHOOL; DECISION MAKING; FEMALE; HUMANS; INFANT; MALE; MULTIVARIATE ANALYSIS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, TRKA; RISK ASSESSMENT; SURVIVAL RATE; TAIWAN; TUMOR MARKERS, BIOLOGICAL;

EID: 31544443597     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2006.10.012     Document Type: Article

References (26)

1. Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States: sex-, race- and 1-year age-specific rates by histologic type. Cancer 1995; 75:2186-95.
2. Grovas A, Fremgen A, Rauck A, et al. The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer 1997; 80:2321-2.
3. Woods WG, Lemieux B, Tuchman M. Neuroblastoma represents distinct clinical-biologic entities: a review and perspective from the Quebec Neuroblastoma Screening Project. Pediatrics 1992; 89:114-8.
4. Brodeur GM. Neuroblastoma: biologic insights into a clinical enigma. Nat Rev Cancer 2003; 3:203-16.
5. Castleberry RP. Pediatric update: neuroblastoma. Eur J Cancer 1997; 33:1430-8.
6. Matthay KK, Sather HN, Seeger RC, Haase GM, Hammond GD. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989; 7:236-44.
7. Haase GM, O'Leary MC, Ramsay N, et al. Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma. J Pediatr Surg 1991; 26:1119-24.
8. La Quaglia MP, Kushner BH, Heller G, et al. The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg 2004; 39:412-7.
9. Kaneko M, Ohakawa H, Iwakawa M. Is extensive surgery required for the treatment of advanced neuroblastoma? J Pediatr Surg 1997; 32:1616-9.
10. Castel V, Tovar JA, Costa E, et al. The role of surgery in stage IV neuroblastoma. J Pediatr Surg 2002; 37:1574-8.
11. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313:1111-6.
12. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328:847-54.
13. Brodeur GM, Prichard J, Berthold F, et al. Revision of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466-77.
14. Shimada H, Chatten J, Newton WA, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984; 73:405-16.
15. Tanaka T, Hiyama E, Sugimoto T, Sawada T, Tanabe M, Ida N. trk A gene expression in neuroblastoma: the clinical significance of immunohistochemical study. Cancer 1995; 76:1086-95.
16. Sartelet H, Grossi L, Pasquier D, et al. Detection of N-myc amplification by FISH in immature areas of fixed neuroblastomas: more efficient than Southern blot/PCR. J Pathol 2002; 198:83-91.
17. Grady-Leopardi EF, Schwab M, Ablin AR, Rosenau W. Detection of N-myc oncogene expression in human neuroblastoma by in situ hybridization and blot analysis: relationship to clinical outcome. Cancer Res 1986; 46:3196-9.
18. Adkins ES, Sawin R, Gerbing RB, London WB, Matthay KK, Haase GM. Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. J Pediatr Surg 2004; 39:931-6.
19. Shamberger RC, Smith EI, Joshi VV, et al. The risk of nephrectomy during local control in abdominal neuroblastoma. J Pediatr Surg 1998; 33:161-4.
20. Matsumura M, Atkinson JB, Hays DM, et al. An evaluation of the role of surgery in metastatic neuroblastoma. J Pediatr Surg 1988; 23:448-53.
21. Riley RD, Heney D, Jones DR, et al. A systemic review of molecular and biologic tumor markers in neuroblastoma. Clin Cancer Res 2004; 10:4-12.
22. Garaventa A, Boni L, Lo Piccolo GP, et al. Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. Ann Oncol 2002; 13:956-64.
23. Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 2002; 24:613-21.
24. Cheung NKV, Kushner BH, LaQuaglia MP, et al. Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biologic markers. Eur J Cancer 1997; 33:2117-20.
25. von Schweinitz D, Hero B, Berthold F. The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg 2002; 12:402-9.
26. Nakagawara A, Ikeda K, Yokoyama T, Tsuda T, Higashi K. Surgical aspects of N-myc oncogene amplification of neuroblastoma. Surgery 1988; 104:34-40.